We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+54.95%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$322M
Cap. Flow
+$13.5M
Cap. Flow %
1.26%
Top 10 Hldgs %
58.42%
Holding
77
New
21
Increased
11
Reduced
14
Closed
24

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$67.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$32.7M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$22.6M
4
VTYX
Ventyx Biosciences
VTYX
+$16.9M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$14.1M

Top Sells

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$23.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$19.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$16.9M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$15.4M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Miscellaneous 16.05%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRCL
76
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-2,525,000
Closed -$7.27M
MRTX
77
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-300,000
Closed -$13.1M
1 2 3
4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q4 2023 Portfolio in Review

As of Q4 2023, Logos Global Management held 77 positions worth $1.07B, up 43% from $750M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Logos Global Management's Q4 2023 filing shows 21 new, 11 increased, 14 reduced and 24 closed positions. Its largest new stake was argenx: 145,000 shares worth $55.2M. The largest sale was Icosavax, Inc. Common Stock, an estimated $23.7M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Financials.

  • Logos Global Management's largest Q4 2023 buy was argenx: 145,000 shares worth $55.2M.
  • Logos Global Management added most to Structure Therapeutics in Q4 2023, an estimated $32.7M increase.
  • Logos Global Management's biggest Q4 2023 reduction was Icosavax, Inc. Common Stock, cutting an estimated $23.7M.
  • Logos Global Management fully exited Sarepta Therapeutics in Q4 2023, selling an estimated $19.2M.
  • Logos Global Management's ten largest holdings make up 58% of its $1.07B portfolio in Q4 2023.
  • Logos Global Management opened 21 new positions and closed 24 in Q4 2023.
  • Logos Global Management's portfolio value rose 43% quarter-over-quarter to $1.07B.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.